

Gilles DULUCDirecteur de la Recherche Clinique
et de l'Innovation

Talence, le 13/05/2025

Jeanne PATARDDirectrice adjointe de la Recherche
Clinique et de l'InnovationDépartement Promotion Interne**Anne GIMBERT**Responsable
Tél 05.57.82.04.34
anne.gimbert@chu-bordeaux.fr**Object :** Interventional Clinical Trial's results posting to the European Clinical
Trial register (EudraCT) of the European Medicines Agency (EMA).


In accordance of Directive 2001/20/CE

Study Title : SOPHA-Méto : Subcutaneous route and pharmacology of
metoclopramide**EudraCT Nbr :** 2014-004282-25**Sponsor Nbr :** CHUBX2014/10 / **ANSM Nbr :** 150043A-42**Transitioned study to the Regulation (EU) 536/2014 :** no**Status of the Study :** prematurely ended

The number of patients was under the planned rate resulted and too low to
perform the statistical analysis planned. (5 patients included out of the 24 planned). No
valorization was possible.

For the Head of the University Hospital of Bordeaux
and by delegation,
The Director of the Clinical research and Innovation

Gilles DULUC

par délégation, Jeanne Patard, directrice adjointe


DIRECTION GENERALE**12, rue Dubernat - 33404 Talence Cedex - Tél 05 56 79 56 79****www.chu-bordeaux.fr**